Pereira B J, Milford E L, Kirkman R L, Quan S, Sayre K R, Johnson P J, Wilber J C, Levey A S
New England Organ Bank, Newton, MA 02158-2803.
N Engl J Med. 1992 Sep 24;327(13):910-5. doi: 10.1056/NEJM199209243271302.
There is a high prevalence of liver disease among the recipients of organs from donors with antibodies to hepatitis C virus (HCV). We undertook a study to determine the frequency of persistent HCV infection, as indicated by the presence of HCV RNA, among both cadaveric organ donors positive for antibodies to HCV (anti-HCV) and the recipients or organs from these donors.
Serum samples from donors and recipients were tested for HCV RNA with the reverse transcriptase polymerase chain reaction, with use of primers from the 5' untranslated region of the HCV genome, and for anti-HCV with the first-generation enzyme-linked immunosorbent assay (ELISA) and two second-generation tests.
HCV RNA was detected in 9 of the 11 organ donors (82 percent) with a positive first-generation ELISA for anti-HCV. Among the organ recipients, the prevalence of HCV RNA increased after transplantation: 7 of 26 patients (27 percent) had positive samples before transplantation, as compared with 23 of 24 patients (96 percent) after transplantation (P less than 0.001). Among 13 recipients who were HCV RNA-negative before receiving organs from the nine HCV RNA-positive donors, HCV infection was detected in all 13 after transplantation, and anti-HCV developed in 8 (62 percent). On the basis of a positive test for HCV RNA, the maximal sensitivity of the three anti-HCV tests was 57 percent (positive in 4 of 7 patients with end-stage organ failure) before transplantation and 70 percent (positive in 16 of 23 patients) after transplantation.
Nearly all the recipients of organs from anti-HCV-positive donors become infected with HCV. The current tests for anti-HCV antibodies underestimate the incidence of transmission and the prevalence of HCV infection among immunosuppressed organ recipients.
在接受丙型肝炎病毒(HCV)抗体阳性供体器官的受者中,肝病的患病率很高。我们进行了一项研究,以确定在抗HCV抗体(抗-HCV)阳性的尸体器官供体以及这些供体器官的受者中,由HCV RNA的存在所表明的持续性HCV感染的频率。
使用来自HCV基因组5'非翻译区的引物,通过逆转录聚合酶链反应检测供体和受者血清样本中的HCV RNA,并使用第一代酶联免疫吸附测定(ELISA)和两种第二代检测方法检测抗-HCV。
在11名第一代ELISA抗-HCV阳性的器官供体中,有9名(82%)检测到HCV RNA。在器官受者中,移植后HCV RNA的患病率增加:26例患者中有7例(27%)移植前样本为阳性,而移植后24例患者中有23例(96%)为阳性(P<0.001)。在从9名HCV RNA阳性供体接受器官前HCV RNA阴性的13名受者中,移植后所有13名均检测到HCV感染,8名(62%)出现抗-HCV。基于HCV RNA检测阳性,三种抗-HCV检测的最大敏感性在移植前为57%(7例终末期器官衰竭患者中有4例阳性),移植后为70%(23例患者中有16例阳性)。
几乎所有接受抗-HCV阳性供体器官的受者都会感染HCV。目前的抗-HCV抗体检测低估了免疫抑制器官受者中传播的发生率和HCV感染的患病率。